Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Valeant Pharmaceuticals International Inc (NYSE:VRX)

Delayed Data
As of Aug 27
 +7.66 / +3.37%
Today’s Change
Today|||52-Week Range
Valeant Pharmaceuticals Intl Inc (VRX): A $1 Billion Bet On The Female Viagra
Aug 27 / Investing Channel
Novartis' Odomzo Gets European Approval for Skin Cancer
Aug 21 / Zacks.com
Sucampo to Acquire R-Tech Ueno for About $278 Million
Aug 27 / Zacks.com
Company News for August 21, 2015
Aug 21 / Zacks.com
Profit From The Massive Pharma Deals With This ETF
Aug 27 / Investing Channel
Here's What Bill Ackman Has Been Buying and Selling
Aug 21 / MotleyFool.com
Valeant Pharmaceuticals' (VRX) Charts Read Like a Textbook Bull
Aug 26 / TheStreet.com
Inovio Reports Encouraging Preclinical Data on DNA Vaccine
Aug 20 / Zacks.com
Valeant Charts Read Like a Textbook Bull
Aug 26 / TheStreet.com
Roche to Buy Kapa Biosystems, Boost Diagnostics Business
Aug 20 / Zacks.com
Exelixis' Cancer Drug Gets Breakthrough Therapy Status
Aug 25 / Zacks.com
Why Valeant Pharmaceuticals (VRX) Isn't Done Growing Earnings Yet
Aug 20 / Zacks.com
Epizyme (EPZM) Gains as Oncology Candidate Advances
Aug 25 / Zacks.com
Female libido pill maker Sprout bought by Valeant for $1 billion
Aug 20 / CNNMoney.com
Vital Therapies Hit By Disappointing Data on Liver Drug
Aug 24 / Zacks.com
AVEO Up on Novartis Collaboration for Cachexia Candidate
Aug 18 / Zacks.com
Valeant Pharmaceuticals International (VRX) Marked As A Barbarian At The Gate
Aug 24 / TheStreet.com
Esperion Therapeutics (ESPR) Catches Eye: Stock Up 14.1%
Aug 18 / Zacks.com
Valeant (VRX) Is in Oversold Territory: What's Next?
Aug 24 / Zacks.com
Endo Gets Favorable Ruling Related to Opana ER in U.S.
Aug 17 / Zacks.com
The Berkshire Hathaway of Biotech Strikes Again
Aug 24 / MotleyFool.com
KemPharm (KMPH) Posts Wider-Than-Expected Loss in Q2
Aug 17 / Zacks.com
Valeant Bets Women's Viagra Is Worth More Than $1 Billion
Aug 22 / MotleyFool.com
Immune Design (IMDZ) Shows Strength: Stock Rises 10.9%
Aug 17 / Zacks.com
Is Valeant's (VRX) $1B Buy of Addyi Maker a Prudent Move?
Aug 21 / Zacks.com
Bristol-Myers Leukemia Drug Sprycel's U.S. Label Updated
Aug 14 / Zacks.com
Gilead's EU Regulatory Application for HIV Drug Validated
Aug 21 / Zacks.com
Is AmEx CEO on the hot seat?
Aug 10 / CNNMoney.com